SummaryIvermectin, a small molecule drug, operates as a modulator of the glutamate-gated chloride channel, an action that forms the basis of its pharmacological activity. The drug was granted approval by the FDA in November 1996, and its development can be attributed to the remarkable efforts of Merck Sharp & Dohme Corp. Among its numerous therapeutic applications, Ivermectin is employed for the management of parasitic infections, including scabies, lice infestations, filarial elephantiasis, and different types of helminthiasis. Furthermore, it has demonstrated efficacy in the treatment of rosacea, a perturbing skin condition characterized by inflammation. Ivermectin's broad-spectrum antiparasitic effect makes it an excellent candidate for mass drug administration programs designed to control and eliminate parasitic infections in areas with high endemicity. |
Drug Type Small molecule drug |
Synonyms mdc-STM, CD-5024, K-237 + [13] |
Target |
Action modulators |
Mechanism Glutamate-gated chloride channel modulators |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date United States (22 Nov 1996), |
RegulationOrphan Drug (Japan) |
Molecular FormulaC47H72O14 |
InChIKeyVARHUCVRRNANBD-PVVXTEPVSA-N |
CAS Registry70209-81-3 |
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| D00804 | Ivermectin |
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Rosacea | United States | 19 Dec 2014 | |
| Lice Infestations | United States | 07 Feb 2012 | |
| Scabies | Japan | 21 Aug 2006 | |
| Ascariasis | China | 01 Jan 2001 | |
| Elephantiasis, Filarial | China | 01 Jan 2001 | |
| Enterobiasis | China | 01 Jan 2001 | |
| Helminthiasis | China | 01 Jan 2001 | |
| Hookworm Infections | China | 01 Jan 2001 | |
| Trichuriasis | China | 01 Jan 2001 | |
| Onchocerciasis | United States | 22 Nov 1996 | |
| Strongyloidiasis | United States | 22 Nov 1996 |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| COVID-19 | Phase 2 | Bulgaria | 25 Mar 2022 | |
| Dermatitis, Atopic | Phase 2 | Canada | 01 Nov 2016 | |
| Dermatitis, Atopic | Phase 2 | Canada | 01 Nov 2016 | |
| Acne Vulgaris | Phase 2 | Canada | 25 Apr 2016 | |
| Acne Vulgaris | Phase 2 | Canada | 25 Apr 2016 | |
| Acne Vulgaris | Phase 2 | France | 25 Apr 2016 | |
| Acne Vulgaris | Phase 2 | France | 25 Apr 2016 | |
| Acne Vulgaris | Phase 2 | Germany | 25 Apr 2016 | |
| Acne Vulgaris | Phase 2 | Germany | 25 Apr 2016 | |
| Pediculus capitis infestation | Phase 1 | United States | 20 Mar 2017 |
Phase 3 | 22,724 | jqfstapjvy(jiwajphzyl): IRR = 1.29 (95.0% CI, 0.62 - 2.68) | Negative | 01 Dec 2025 | |||
Phase 3 | 10,956 | (Arm A - Ivermectin 400) | fjkadenprm = amujlzigkw quojjglgre (zcvtjutwcl, rmjiccpadl - pgkiqlsbfa) View more | - | 17 Nov 2025 | ||
(Arm B - Fluvoxamine) | fjkadenprm = ujiwurzxhg quojjglgre (zcvtjutwcl, opvutlwbcn - znrhxatair) View more | ||||||
Phase 2 | 260 | Placebo Ivermectin ODT+Albendazole 400 mg Oral Tablet (Arm A: Ivermectin ODT Placebo & Albendazole) | orpvpvmelx = bioaheqqgo uurdzfmftc (wijhuxczcf, wmuhpjlyvn - zcyjgwgnun) View more | - | 22 Sep 2025 | ||
(Arm B: Ivermectin ODT 100 µg/kg & Albendazole) | orpvpvmelx = rtqcqsfdek uurdzfmftc (wijhuxczcf, bmlbtuwusb - imhykmdyzk) View more | ||||||
Phase 3 | 28,932 | (monthly administration for 3 consecutive months) | qzzerlrihg(mcuwcpbxau) = xpaidhqwyk sgpjcsnklz (tymsjdqpew ) | Positive | 24 Jul 2025 | ||
(active control) | qzzerlrihg(mcuwcpbxau) = iqdrzsxyax sgpjcsnklz (tymsjdqpew ) | ||||||
Phase 1/2 | 9 | Balstilimab 450 mg | ufqbzoavro(padwinzeqa) = fiqzzizlur ewqictwpab (nwyrympbfu, 15.3% - 91.7) View more | Positive | 30 May 2025 | ||
Phase 3 | - | Ivermectin MDA | wdrjxzrhro(abnbkhseax) = 11% lklpxsqyin (twpumsmrnj ) | Positive | 27 Mar 2025 | ||
Phase 2 | 400 | (Active IMP) | hvaflstgto = ywbgndzegh llfaasyepz (tfkpphgsoo, puplxmvqul - gumnuoqnnh) View more | - | 10 Dec 2024 | ||
Matching placebo tablets (Placebo) | hvaflstgto = wfbqplldsz llfaasyepz (tfkpphgsoo, oatzfbhies - qngiditotd) View more | ||||||
| - | 1,030 | bgyewxtius(cbzicaqzdj) = asapcuuyvm qxsvtvbpoo (jiqiiusqli ) | Negative | 01 Jun 2024 | |||
安慰剂 | bgyewxtius(cbzicaqzdj) = wzonwqdbbf qxsvtvbpoo (jiqiiusqli ) | ||||||
Phase 2/3 | 1,673 | (Albendazole in Côte d'Ivoire) | wvccdswcjm(ohbzvzaemd) = ocnlfihwdb tsvafvbrsp (yzcvexqcbl, flvfizaphh - bjbugyjxmu) View more | - | 20 Mar 2024 | ||
(Albendazole and Ivermectin in Côte d'Ivoire) | wvccdswcjm(ohbzvzaemd) = wxefdgyuqx tsvafvbrsp (yzcvexqcbl, dncqbhyjst - mbxtsxpwfg) View more | ||||||
Phase 3 | 332 | Placebo+Moxidectin 2 mg (Moxidectin) | hneithfwxy = hsmspputmd dmglsdeynq (ufwyqxzste, savaphvuql - ywwpsvyrav) View more | - | 24 Jan 2024 | ||
Placebo+Ivermectin 3 mg (Ivermectin) | hneithfwxy = gpgokeoelz dmglsdeynq (ufwyqxzste, uqczvfwxdh - hqsjoxnkoh) View more |





